In vivo Efficacy
- Categories:In Vivo efficacy
- Time of issue:2020-12-23 11:51:25
A cell line-derived xenograft or CDX model is one of the most widely used models for the study of anti-cancer therapies. It involves culturing human tumour cell lines and transplanting them into immunosuppressed mice or culturing mouse cell lines and transplanting them into immune-competent mice to study a compound’s effect on tumor growth in vivo.
KYinno has developed over 300 engineered BaF3 cell lines by introducing overexpression or mutation of various kinases. We also created a panel of isogenic cancer cell lines with site-specific mutations introduced through CRISPR gene-editing technologies. All these engineered cell lines have been well validated for in vivo efficacy studies to support both small molecule and biologics drug discovery programs.
BaF3: RET inhibitor treatment in engineered BaF3-RET tumour model
MC38: PD-L1 antibody treatment in MC38 syngeneic tumour model
KYinno Biotechnology Co., Ltd
Cell phone No: +(86)10-58222701 / 58222702
Room 609, No.3 Building, Yizhuang Biomedical Park, No.88, Kechuang Six Street, BDA,
Beijing, China, 101111